Previous Close | 13.12 |
1-Year Change | -53.9% |
6-Months Change | -49.48% |
3-Months Change | -42.96% |
Moving Avg (50d) | 18.26 |
Moving Avg (200d) | 23.17 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.34B |
Beta (3-Years) | 2.05 |
Revenue Growth (ttm) | 373.72% |
Net Profit Margin (ttm) | -1160.55% |
Return On Assets (ttm) | -44.51% |
EPS (ttm) | -5.44 |
PE Ratio (ttm) | -2.41 |
Dividend Yield | % |
Asset Description: | Intellia Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2024-11-14 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
13.382 | 13.776 | 14.038 | 14.432 | 15.088 | 15.744 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues.... Wikipedia